1 Psychiatric Treatment Centre, Sternberk Czechoslovakia; Ferring Internatinational, Ltd., London; and the Department of Physiology and Biophysics, Mt. Sinai School of Medicine, City University of New York
Desmopressin (1-desamino-[8-D-Arg]-vasopressin) (DDAVP) was given by nose drops to 22 children with persistent nocturnal enuresis (mean age, 6.6 ± 2.9 years; range. 4 to 12 years) the evening before sleep. With saline alone as placebo and with comparison to enuretic frequency before the onset of the trial, fortnightly periods were compared under double-blind conditions with the children at home. Pretreatment and placebo fortnights showed wetting frequencies (nights per fortnight) of 10.6 ± 4.9 and 11.0 ± 4.4, respectively. The value of the fortnight during desmopressin therapy was 4.2 ± 4.5, which was significantly different from either of the previous means (P .01 ). Of the 22 subjects, four failed to react to therapy at all. There was decreased enuretic frequency in the remaining 18, of whom 12 decreased markedly or ceased wetting. One month after the trial, seven of the respondents were dry with desmopressin therapy. There was clear evidence of a large nocturnal volume of dilute urine before treatment in six of the respondents in whom such measurements could be reliably made. These children responded to dehydration with urine concentration. however, so that the suggestion can be made that a failure to develop a normal diurnal pattern of urine volume and concentration may underly some cases of enuresis.
Submitted on March 15, 1978
This article has been cited by other articles:
![]() |
O. Osterberg, R. M. Savic, M. O. Karlsson, U. S. H. Simonsson, J. P. Norgaard, J. V. Walle, and H. Agerso Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J. Clin. Pharmacol., October 1, 2006; 46(10): 1204 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Neveus, G. Lackgren, T. Tuvemo, and A. Stenberg Osmoregulation and Desmopressin Pharmacokinetics in Enuretic Children Pediatrics, January 1, 1999; 103(1): 65 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Uygur, I. H. Ozgu, H. Ozen, S. Ozen, C. Toklu, A. Ergen, S. Tekgul, and D. Remzi Long-Term Treatnent of Nocturnal Enuresis withi Desmopressin Intranasal Spray Clinical Pediatrics, August 1, 1997; 36(8): 455 - 459. [Abstract] [PDF] |
||||
![]() |
K. HjalmAs and B. Bengtsson Efficacy, Safety, and Dosing of Desmopressin For Nocturnal Enuresis in Europe Clinical Pediatrics, July 1, 1993; 32(1_suppl): 19 - 24. [Abstract] [PDF] |
||||
![]() |
D. A. Bloom The American Experience With Desmopressin Clinical Pediatrics, July 1, 1993; 32(1_suppl): 28 - 31. [Abstract] [PDF] |
||||
![]() |
P. S. Beach, R. E. Beach, and L. R. Smith Hyponatremic Seizures in a Child Treated With Desmopressin to Control Enuresis: A Rational Approach to Fluid Intake Clinical Pediatrics, September 1, 1992; 31(9): 566 - 569. [PDF] |
||||